In 10-year registry follow-up of 699 PlanB trial patients with HR-positive, HER2-negative early breast cancer, invasive disease-free survival was similar with six cycles of TC and with EC-T (90.8% vs 92.1%, P = 0.546); overall survival was 96.8% vs 96.3%.
RCTn = 699
Nitz et al. Long-term outcome data for patients with hormone receptor-positive early breast cancer participating in the WSG PlanB trial after preselection by gene expression analysis: 10-year survival results from the WSG PlanB registry